Suppr超能文献

肠道共生菌屎肠球菌可重塑先天性免疫以减轻小鼠肥胖和代谢疾病。

Gut commensal Phascolarctobacterium faecium retunes innate immunity to mitigate obesity and metabolic disease in mice.

作者信息

Liébana-García Rebeca, López-Almela Inmaculada, Olivares Marta, Romaní-Pérez Marina, Manghi Paolo, Torres-Mayo Alba, Tolosa-Enguís Verónica, Flor-Duro Alejandra, Bullich-Vilarrubias Clara, Rubio Teresa, Rossini Valerio, Segata Nicola, Sanz Yolanda

机构信息

Microbiome Innovation in Nutrition and Health Research Unit, Institute of Agrochemistry and Food Technology, Spanish National Research Council (IATA-CSIC), Valencia, Spain.

Department CIBIO, University of Trento, Trento, Italy.

出版信息

Nat Microbiol. 2025 May 6. doi: 10.1038/s41564-025-01989-7.

Abstract

The gut microbiota may protect against obesity and chronic metabolic conditions by regulating the immune response to dietary triggers. Yet the specific bacteria that control the overactivation of the immune system in obesity and their mode of action remain largely unknown. Here we surveyed 7,569 human metagenomes and observed an association between the gut symbiont Phascolarctobacterium faecium and non-obese adults regardless of nationality, sex or age. In a mouse model of diet-induced obesity, we confirmed the specificity of P. faecium DSM 32890 anti-obesogenic properties compared with other species of the same genus. P. faecium reversed the inflammatory phenotype associated with obesity. Specifically, P. faecium promoted polarization of alternatively activated macrophages (M2), which reversed the obesity-induced increase in gut-resident type 1 innate lymphoid cells. This resulted in mitigation of glucose intolerance, adiposity and body weight gain irrespective of treatment with live or pasteurized bacteria. The metabolic benefits were independent of the adaptive immune system, but they were abolished by an inhibitor of M2 polarization in mice. P. faecium directly promoted M2-macrophage polarization through TLR2 signalling and these effects seemed to be independent of gut microbiota changes. Overall, we identify a previously undescribed gut commensal bacterium that could help mitigate obesity and metabolic comorbidities by retuning the innate immune response to hypercaloric diets.

摘要

肠道微生物群可能通过调节对饮食触发因素的免疫反应来预防肥胖和慢性代谢疾病。然而,在肥胖症中控制免疫系统过度激活的特定细菌及其作用方式在很大程度上仍不清楚。在这里,我们调查了7569个人类宏基因组,观察到肠道共生菌屎肠球菌与非肥胖成年人之间存在关联,无论其国籍、性别或年龄如何。在饮食诱导的肥胖小鼠模型中,我们证实了屎肠球菌DSM 32890与同一属的其他物种相比具有抗肥胖特性的特异性。屎肠球菌逆转了与肥胖相关的炎症表型。具体而言,屎肠球菌促进了交替激活的巨噬细胞(M2)的极化,这逆转了肥胖诱导的肠道驻留1型天然淋巴细胞增加。这导致葡萄糖不耐受、肥胖和体重增加减轻,无论使用活细菌还是巴氏杀菌细菌进行治疗。代谢益处独立于适应性免疫系统,但在小鼠中被M2极化抑制剂消除。屎肠球菌通过TLR2信号直接促进M2巨噬细胞极化,这些作用似乎与肠道微生物群的变化无关。总体而言,我们鉴定出一种以前未描述的肠道共生细菌,它可以通过调整对高热量饮食的先天免疫反应来帮助减轻肥胖和代谢合并症。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验